Skip to content
Profiles

Armatus Bio

Armatus Bio is a preclinical stage biotech company developing vectorized microRNA therapeutics to treat autosomal dominant (AD) neuromuscular diseases, with a lead candidate showing promising results in treating the genetic cause of CMT1A.

Armatus Bio has had an evolving partnership with CMTA over multiple years. Together, they have built deep engagement that has not only better-informed Armatus Bio’s understanding of the burden and urgent needs for care of CMT but also helped to connect them into the broad multidisciplinary network of leaders that the CMT convenes to drive progress.

CMT1A